Indication
Lower respiratory tract infections, Skin & skin structure infections, Urinary tract infections, Bacterial septicemia, Bone & joint infections, Gynecologic infections, Intra-abdominal infections, Central nervous system infections Infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (CAPD).
Dosage and Administration
| Dose | Frequency |
Adults |
|
|
Usual recommended dosage | 1 g IV or IM | 8-12 hourly |
Uncomplicated pneumonia | 500mg-1gIV or IM | 8 hourly |
Lung infections | 30-35 mg /kg IV | 8 hourly |
Mild skin and skin-structure infections | 500 mg - 1 g IV or IM | 8 hourly |
Complicated urinary tract infections | 500 mg IV or IM | 12 hourly |
Bone & joint infections, severe immunocompromised patients, Meningitis, Serious gynecologic and intra-abdominal infections | 2 g IV | 8 hourly |
Neonates (0-4 weeks) | 30 mg/kg IV | 12 hourly |
Infants and children (1 month - 12 years) | 30-50 mg/kg IV to maximum of 6 g per day | 8 hourly |
Dose in dialysis : 1 g loading dose followed by 1 g after each hemodialysis period.
Composition
Trizidim® 250 mg IM / IV : Ceftazidime USP 250 mg.
Trizidim® 500 mg IM / IV : Ceftazidime USP 500 mg.
Trizidim® 1 g IM / IV : Ceftazidime USP 1 g.
Water for injection : Each ampoule contains 5 ml or 10 ml sterile water for injection BP for reconstitution